Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The crucial role of muscle glucocorticoid signaling in accelerating obesity and glucose intolerance via hyperinsulinemia
Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka
Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka
View: Text | PDF
Research Article Endocrinology Muscle biology

The crucial role of muscle glucocorticoid signaling in accelerating obesity and glucose intolerance via hyperinsulinemia

  • Text
  • PDF
Abstract

Metabolic crosstalk from skeletal muscle to multiple organs is important for maintaining homeostasis, and its dysregulation can lead to various diseases. Chronic glucocorticoid administration often induces muscle atrophy and metabolic disorders such as diabetes and central obesity; however, the detailed underlying mechanism remains unclear. We previously reported that the deletion of glucocorticoid receptor (GR) in skeletal muscle increases muscle mass and reduces fat mass through muscle-liver-fat communication under physiological conditions. In this study, we show that muscle GR signaling plays a crucial role in accelerating obesity through the induction of hyperinsulinemia. Fat accumulation in liver and adipose tissue, muscle atrophy, hyperglycemia, and hyperinsulinemia induced by chronic corticosterone (CORT) treatment improved in muscle-specific GR-knockout (GR-mKO) mice. Such CORT-induced fat accumulation was alleviated by suppressing insulin production (streptozotocin injection), indicating that hyperinsulinemia enhanced by muscle GR signaling promotes obesity. Strikingly, glucose intolerance and obesity in ob/ob mice without CORT treatment were also improved in GR-mKO mice, indicating that muscle GR signaling contributes to obesity-related metabolic changes, regardless of systemic glucocorticoid levels. Thus, this study provides insight for the treatment of obesity and diabetes by targeting muscle GR signaling.

Authors

Hiroki Yamazaki, Masaaki Uehara, Noritada Yoshikawa, Akiko Kuribara-Souta, Motohisa Yamamoto, Yasuko Hirakawa, Yasuaki Kabe, Makoto Suematsu, Hirotoshi Tanaka

×

Figure 6

Hyperinsulinemia induced by chronic CORT treatment counteracts muscle atrophy by inhibiting muscle GR downstream gene expression.

Options: View larger image (or click on image) Download as PowerPoint
Hyperinsulinemia induced by chronic CORT treatment counteracts muscle at...
(A) The gene expression of gastrocnemius muscle (Gas) from GRfl/fl or GR-mKO male mice pretreated with streptozotocin (STZ) or vehicle (day 0) and provided drinking water with CORT (day 5–26) ad libitum, as indicated in Figure 5A. Data presented as mean ± SEM (n = 5–7). *P < 0.05 by 2-way ANOVA with Tukey-Kramer post hoc test. (B and C) C2C12 myoblasts were pretreated with insulin at the indicated concentrations and followed by stimulation with 10 nM dexamethasone (DEX). The experimental protocol (B) and gene expression levels (C). Data presented as mean ± SEM (n = 3). *P < 0.05 versus DEX (−) after 0 nM insulin treatment; †P < 0.05 versus DEX (+) after 0 nM insulin treatment. Significance determined by 1-way ANOVA and Dunnett’s post hoc test. (D and E) Seven-week-old male mice were pretreated with 200 mg/kg BW STZ or vehicle (day 0) and followed by injection of 1 mg/kg BW DEX or normal saline (day 5). The experimental protocol (D). mRNA levels for Gas in each group (E). Data presented as mean ± SEM (n = 3−5). *P < 0.05 by 2-way ANOVA with Tukey-Kramer post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts